|Day's range||16.50 - 17.10|
CRISPR Therapeutics (NASDAQ: CRSP) has a couple of things in common with a company that's made the headlines over the past few years: coronavirus vaccine maker Moderna (NASDAQ: MRNA). Today, CRISPR's market value sits at about $3.4 billion. Since, Moderna has grown to become a $58 billion company, with a blockbuster product and three more potential ones on the horizon.
Moderna (NASDAQ: MRNA) helped some investors make a fortune over the past few years. The stock has climbed more than 400% since March 2020 -- that's when the company's coronavirus vaccine program gained traction. Recently, though, investors have worried about Moderna's post-pandemic revenue, and that's weighed on share performance.
Moderna (MRNA) collaborates with Generation Bio to develop non-viral genetic medicines. For this, it leverages the latter's closed-end DNA (ceDNA) and cell-targeted LNPs (ctLNP) technologies.